BDBM326318 3-{4-(3-chlorophenyl)-7- methyl-5-[(trans-4- methylcyclohexyl)methyl]- 5H-pyrrolo[3,2- d]pyrimidin-2-yl}-1,2,4- oxadiazol-5(4H)-one::US9637493, 5.2
SMILES: C[C@H]1CC[C@H](Cn2cc(C)c3nc(nc(-c4cccc(Cl)c4)c23)-c2noc(=O)[nH]2)CC1
InChI Key:
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
p53-binding protein Mdm2 (Homo sapiens (Human)) | BDBM326318 (3-{4-(3-chlorophenyl)-7- methyl-5-[(trans-4- methy...) | PDB GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 107 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Sharp & Dohme Corp. US Patent | Assay Description Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM... | US Patent US9637493 (2017) BindingDB Entry DOI: 10.7270/Q28917Z1 | |||||||||||
More data for this Ligand-Target Pair |